[go: up one dir, main page]

MX2019003615A - Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas. - Google Patents

Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.

Info

Publication number
MX2019003615A
MX2019003615A MX2019003615A MX2019003615A MX2019003615A MX 2019003615 A MX2019003615 A MX 2019003615A MX 2019003615 A MX2019003615 A MX 2019003615A MX 2019003615 A MX2019003615 A MX 2019003615A MX 2019003615 A MX2019003615 A MX 2019003615A
Authority
MX
Mexico
Prior art keywords
nucleic acid
surface antigen
protein
vaccine
acid molecule
Prior art date
Application number
MX2019003615A
Other languages
English (en)
Inventor
B Weiner David
Yan Jian
Obeng-Adjei Nyamekye
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2019003615A publication Critical patent/MX2019003615A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente secuencias de ácido nucleico que codifican las proteínas centrales del virus de la hepatitis B (VHB), proteína del antígeno de superficie, fragmentos y combinaciones de estos, así como también construcciones genéticas/vectores y vacunas que expresan las secuencias de proteínas. Estas proteínas son capaces de inducir una respuesta inmunitaria en el hígado y en forma periférica mediante la captación de agentes celulares y humorales. Además, se proporcionan métodos para inmunizar individuos contra el VHB en forma profiláctica y/o terapéutica. La vacuna combinada se puede utilizar también para vacunas de diseño particulares, para niveles de respuestas inmunitarias particulares para la prueba de provocación del VHB.
MX2019003615A 2012-09-19 2015-03-18 Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas. MX2019003615A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/622,965 US9238679B2 (en) 2011-02-11 2012-09-19 Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same

Publications (1)

Publication Number Publication Date
MX2019003615A true MX2019003615A (es) 2019-07-18

Family

ID=48945721

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003489A MX363671B (es) 2012-09-19 2013-09-19 Proteína central y proteína del antígeno de superficie del virus de la hepatitis b y vacunas comprenden éstas.
MX2019003615A MX2019003615A (es) 2012-09-19 2015-03-18 Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003489A MX363671B (es) 2012-09-19 2013-09-19 Proteína central y proteína del antígeno de superficie del virus de la hepatitis b y vacunas comprenden éstas.

Country Status (17)

Country Link
US (2) US9238679B2 (es)
EP (1) EP2897640B1 (es)
JP (4) JP6795303B2 (es)
KR (3) KR102382942B1 (es)
CN (2) CN104640565B (es)
AU (1) AU2013318022B2 (es)
BR (1) BR112015005987A2 (es)
CA (2) CA2882839C (es)
EA (2) EA036030B1 (es)
MX (2) MX363671B (es)
MY (1) MY170659A (es)
NZ (1) NZ705526A (es)
PH (2) PH12020551152A1 (es)
SG (2) SG10201702325UA (es)
UA (1) UA120909C2 (es)
WO (1) WO2014047286A1 (es)
ZA (1) ZA201501639B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
WO2012109668A1 (en) 2011-02-11 2012-08-16 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
CN118063563A (zh) 2016-04-06 2024-05-24 华盛顿大学 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗
US20190240353A1 (en) * 2016-07-05 2019-08-08 University Of Massachusetts Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
CN106421774B (zh) * 2016-09-08 2019-05-28 中国科学院生物物理研究所 PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途
EP3515466A4 (en) * 2016-09-21 2020-05-27 The Trustees of The University of Pennsylvania OPTIMIZED SYNTHETIC INMUNOGENOUS CONSENSUS COMPOSITIONS AGAINST FIBROBLAST ACTIVATION PROTEIN
EP3607968A4 (en) * 2017-06-05 2021-03-31 Beacle Inc. VIRAL-TYPE PARTICLES INTENDED FOR USE TO INDUCE AN IMMUNE RESPONSE AGAINST HBV
CN111542340B (zh) 2017-11-16 2023-12-19 华盛顿大学 治疗性乙型肝炎病毒(hbv)疫苗
US20220047695A1 (en) * 2018-12-21 2022-02-17 The Wistar Institute Of Anatomy And Biology Compositions comprising self-assembling vaccines and methods of using the same
KR102175170B1 (ko) * 2019-02-19 2020-11-05 대한민국 HBV enhancer 억제인자 ACK1을 포함하는 B형 간염 치료용 조성물
EP3986454A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
CN111494616A (zh) * 2020-04-27 2020-08-07 重庆医科大学附属永川医院 一种新冠病毒免疫增强型基因疫苗及其制备方法
CN116768983A (zh) * 2020-10-28 2023-09-19 王立良 一种用于慢性乙型肝炎预防和/或治疗的蛋白、编码基因、重组腺相关病毒及其应用
TWI867312B (zh) * 2021-07-01 2024-12-21 國立成功大學 體外定量b肝病毒大表面蛋白的套組，用於分析hbv感染階段及肝癌預後的生物指標組，以及用於預測、診斷或治療慢性肝病的單株抗體組
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
CN117903323B (zh) * 2024-01-19 2024-08-06 珠海市人民医院 用于靶向降解乙肝病毒s蛋白的药物制剂及用途

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
NL9020389A (nl) 1989-03-08 1991-12-02 Health Research Inc Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen.
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
ES2090129T3 (es) 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
EP0935659A1 (en) 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
CN1198665C (zh) 1997-04-03 2005-04-27 依莱克脱罗弗克脱联合股份有限公司 将药物和核酸导入骨骼肌的方法
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
JP4647870B2 (ja) * 1999-11-24 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｈｂｖ／ｈｃｖウイルス様粒子
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
IL164256A0 (en) 2002-03-28 2005-12-18 Brenntag Biosector As Combined dna/protein compositions
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CN100381463C (zh) 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK2364769T3 (en) 2003-05-30 2016-04-11 Vgxi Inc Apparatus and methods for biomaterialeproduktion
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
KR20050026681A (ko) * 2003-09-09 2005-03-15 학교법인 포항공과대학교 서방성 미립구 형태의 ｉｌ-12 면역증강제를 포함하는백신 조성물
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CN101421402A (zh) * 2006-01-11 2009-04-29 分子作物育种代理有限公司 产生转基因禾本科细胞和植物的方法
AU2007256717B2 (en) * 2006-06-02 2013-06-20 International Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
US8586055B2 (en) 2007-01-12 2013-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA immunization protocols
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
WO2008103380A2 (en) * 2007-02-21 2008-08-28 Fox Chase Cancer Center Hepatitis b virus compositions and methods of use
CN101702938A (zh) 2007-05-23 2010-05-05 Vgx药品公司 包含高浓度的生物活性分子的组合物及其制备工艺
US8138318B2 (en) * 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
MX2010007461A (es) 2008-01-11 2010-10-20 VGX Pharmaceuticals LLC Nuevas vacunas contra multiples subtipos del virus del dengue.
WO2009130588A2 (en) 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2331123A4 (en) * 2008-07-24 2012-11-07 Aduro Biotech COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
WO2010016071A2 (en) 2008-08-05 2010-02-11 Swati Subodh Identification of genomic signature for differentiating highly similar sequence variants of an organism
WO2010042751A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010050939A1 (en) 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
AU2009313714B2 (en) * 2008-11-17 2016-05-19 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
CN101502650B (zh) 2009-03-10 2011-12-28 邢益平 密码子优化的乙型肝炎核酸疫苗
CA2760315C (en) 2009-04-30 2019-05-28 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Modified immunization vectors
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN101954093A (zh) * 2010-09-14 2011-01-26 中国人民解放军第二军医大学 乙型肝炎核酸疫苗及其构建方法
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
WO2012109668A1 (en) * 2011-02-11 2012-08-16 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
AU2012214394B2 (en) * 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection

Also Published As

Publication number Publication date
JP2022084800A (ja) 2022-06-07
EP2897640B1 (en) 2022-03-23
MX2015003489A (es) 2015-06-22
US20130209395A1 (en) 2013-08-15
CN107337719B (zh) 2022-01-04
MY170659A (en) 2019-08-26
EP2897640A1 (en) 2015-07-29
HK1210702A1 (en) 2016-05-06
ZA201501639B (en) 2016-01-27
US9238679B2 (en) 2016-01-19
KR102581951B1 (ko) 2023-09-22
JP2025069414A (ja) 2025-04-30
PH12020551152A1 (en) 2022-06-20
JP7636804B2 (ja) 2025-02-27
SG11201502113YA (en) 2015-05-28
WO2014047286A1 (en) 2014-03-27
EA201590597A1 (ru) 2015-11-30
CA3158935A1 (en) 2014-03-27
JP7050310B2 (ja) 2022-04-08
KR102382942B1 (ko) 2022-04-05
CN104640565A (zh) 2015-05-20
JP2019163286A (ja) 2019-09-26
US9675690B2 (en) 2017-06-13
AU2013318022A1 (en) 2015-03-19
EA036030B1 (ru) 2020-09-16
CA2882839A1 (en) 2014-03-27
KR20220045080A (ko) 2022-04-12
PH12015500308B1 (en) 2021-06-23
EA202090759A2 (ru) 2020-07-31
CA2882839C (en) 2022-07-05
SG10201702325UA (en) 2017-04-27
AU2013318022B2 (en) 2017-03-09
JP6795303B2 (ja) 2020-12-02
KR20230141895A (ko) 2023-10-10
BR112015005987A2 (pt) 2017-08-08
HK1246318A1 (zh) 2018-09-07
CN104640565B (zh) 2017-09-05
EA202090759A3 (ru) 2020-10-30
KR20150056611A (ko) 2015-05-26
EP2897640A4 (en) 2016-09-07
CN107337719A (zh) 2017-11-10
UA120909C2 (uk) 2020-03-10
JP2015530410A (ja) 2015-10-15
NZ705526A (en) 2016-01-29
US20160114030A1 (en) 2016-04-28
MX363671B (es) 2019-03-29
PH12015500308A1 (en) 2015-04-20

Similar Documents

Publication Publication Date Title
MX2019003615A (es) Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
MY173004A (en) Mycobacterial antigen vaccine
WO2012034025A3 (en) Human cytomegalovirus vaccine
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
WO2009117116A3 (en) Heat shock protein gp96 vaccination and methods of using same
WO2020065349A8 (en) Vaccines and methods
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
HK1250662A1 (zh) 用於治疗癌症的免疫原性融合蛋白
HK1210475A1 (en) Herpes simplex virus vaccine
CO6670515A2 (es) Vectores de parapoxvirus
MX2019007924A (es) Vacunas contra la influenza.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same